BerGenBio To Present Preclinical Covid-19 Data At The Conference On Retroviruses And Opportunistic Infections (CROI 2021) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Novadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class clinical trial simulation platform
NOVA to develop COVID-19 disease model to support Sanofi s vaccine and therapeutic efforts
Lyon, France - 16 February 2021: Novadiscovery ( NOVA ), a leading health tech company offering JINKO, a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, today announces that it has raised €2.5 million in a Series A2 financing round from Sanofi.
The funds will be used to advance NOVA s
in silico clinical trial simulation platform, JINKO; to facilitate the Company s expansion into the US; and develop a COVID-19 disease model in collaboration with Sanofi. JINKO s workflows are designed to closely resemble those of real life clinical studies and it offers an integrated suite of applications from Discovery to Market Access.
Immunocore Limited: Immunocore announces key appointments to management and Board
Ralph Torbay appointed Head of Commercial to spearhead the launch of tebentafusp
Dr. Roy S. Herbst appointed as a Non-Executive Director to the Board
OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US - 16 February 2021 - Immunocore Holdings plc (Nasdaq: IMCR), (or the Company or Immunocore ), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announces the appointment of Ralph Torbay as its new Head of Commercial and the appointment of Dr. Roy S. Herbst as a member of its Board of Directors, effective January 28, 2021.
SparingVision Conference Participation in H1 2021
SparingVision Conference Participation in H1 2021
Paris, February 16, 2021 - SparingVision ( the Company ), a genomic medicine company developing vision saving treatments for ocular diseases, announces the conferences that its management team will be participating in in the first half of 2021.
OIS Gene Therapy Innovation Showcase
, 18 February
Gene Therapy Outlook panel, Prof. José Alain Sahel, scientific co-founder (2:30-3:30 PM EST)
4th Annual Gene Therapy for Rare Disorders
, 22-25 February
, Dr Dan Chung, Chief Medical Officer, (Feb 22, 3pm EST)
Keeping CMC Activities Off the Critical Path for Gene Therapy Development (Feb 23, 2PM EST) & CMC and Analytical Chair, Dr Rajiv Gangurde, Chief Technology Officer
Abingdon Health plc: AbC-19 Rapid Test Available for Purchase by Healthcare Professionals
Abingdon Health plc ( the Company ), a leading international developer and manufacturer of high quality and effective rapid tests, announces that the AbC-19 Rapid Test for the detection of SARS-CoV-2 antibodies is now available for purchase by healthcare professionals on the Abingdon Health website.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216005611/en/
The AbC-19 Rapid Test Process (Graphic: Business Wire)
The AbC-19 Rapid Test is a self-contained, highly accurate lateral flow immunoassay designed to give results within 20 minutes at the point of use. The test is designed to confirm the presence of IgG antibodies to the full trimeric spike protein of the SARS-CoV-2 virus. These are the type of antibodies which neutralise the virus and can produce immunity as found after vaccination or following an immune response to COV